Drug Topics - October 8, 2007 - (Page 30)

30 DRUG TOPICS OCTOBER 8, 2007 www.drugtopics.com Government and Law Combating counterfeit drugs an international problem Marianne Rollings, R.Ph. bout a dozen years ago, a Nigerian member of the International Pharmaceutical Federation (FIP) made an impassioned plea for the organization to take up the challenge of identifying and destroying the seamy world of counterfeit drugs. The call did not fall on deaf ears. Since that time activities have been carried out in many areas of the globe. This year’s FIP meeting, held in Beijing, addressed the progress in identifying and dealing with issues related to ersatz (or replacement) drug products. During a joint session of the FIP Board of Pharmaceutical Practice and the FIP Board of Pharmaceutical Sciences, representatives from the United States, the United Kingdom, China, and India presented updates on the current status of the problem. World trade figures indicate that as much as 10% of drug products in the global market may be counterfeit. Statistics indicate that India may have up to 35% of its products in question. However, the Indian government estimates that from 1995 to 2003, the extent of the problem varied between 0.24% and 0.47% for counterfeit and from 8.9% to 10.64% for substandard drugs. A ous to life-saving products. The Indian government funded a survey to determine the extent of the problem. A study was undertaken in 2003 to determine the relative prevalence by state/region, approximate the volume and percent through retail outlets, and ascertain the prevalence in various therapeutic segments and cost ranges. It classed locations by degree of the area’s regulatory strength for the problem. A representative list of therapeutic categories and price variables was used to determine the candidate drugs. “Mystery customers” were used to gather the samples, guides for physical verification of samples were designed, and approved drug-testing laboratories were employed. Sheth told the audience that the results of the survey may have been skewed to some degree by the methods used in sample gathering. The study results showed an average extent of counterfeit drugs to be 3.1% based on physical inspection, and almost the same degree was found in the areas regardless of strong or weak regulation. Lab values indicated only 0.3% did not meet pharmaceutical standards. High on the list of questionable products were those for treatment of TB and certain antibiotics. The study did not address products to be exported. Model program Prafull Sheth, professional secretary, South East Asia Regional Forum, Delhi, reported on a model program to estimate the extent of counterfeit medicines in India. Counterfeits include mimicking the full spectrum of innocu- Big business Reporting from the United States, Michael Anisfeld, pharmacy consultant, Globepharm, Deerfield, Ill., said drug counterfeiting is big business. He quoted a figure of 8%-15% of global sales as counterfeit, with no continent immune. In a global market worth $620 billion, those figures would project to $50-$93 billion. The Partnership for Safe Medicines projects $75 billion worth of counterfeit drugs by 2010. While developing countries find counterfeits in drugs of need such as antimalarials, antibiotics, and anti-HIV/AIDS drugs, the developed world sees more counterfeits in lifestyle drugs or the most costly products. Noting the proliferation of Internet suppliers, Anisfeld said that approximately 70% of these products may be of questionable provenence. He reminded attendees that more than 300 people had died in Panama in 2006 due to counterfeiting of glycerin by the substitution of diethylene glycol from China. He tracked the movement of the product through wholesalers and brokers and decried the lack of an auditing trail and the absence of sampling and analysis of the product before use. Counterfeit packaging is a major problem, along with The Great Hall of the People, Tiananmen Square, Beijing, was the site for the opening ceremony for the latest FIP meeting. Photo: Marianne Rollings http://www.drugtopics.com

Table of Contents Feed for the Digital Edition of Drug Topics - October 8, 2007

Drug Topics - October 8, 2007 Latebreakers Latebreakers in Depth Letters Rx Care Community Practice JP at Large 150 Years of American Pharmacy Hospital Practice Are You Getting Pharmacy's Message Across? Self-Care Government and Law Legal Q&A The Pharmacist as First Responder in Disaster Relief Technology Update New Products Advertisers Index Statement of Ownership Classified Viewpoint

Drug Topics - October 8, 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.